64 related articles for article (PubMed ID: 12065335)
21. Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
Pompilio A; Crocetta V; Confalone P; Nicoletti M; Petrucca A; Guarnieri S; Fiscarelli E; Savini V; Piccolomini R; Di Bonaventura G
BMC Microbiol; 2010 Apr; 10():102. PubMed ID: 20374629
[TBL] [Abstract][Full Text] [Related]
22. A Stenotrophomonas maltophilia multilocus sequence typing scheme for inferring population structure.
Kaiser S; Biehler K; Jonas D
J Bacteriol; 2009 May; 191(9):2934-43. PubMed ID: 19251858
[TBL] [Abstract][Full Text] [Related]
23. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients.
Spicuzza L; Sciuto C; Vitaliti G; Di Dio G; Leonardi S; La Rosa M
Eur J Clin Microbiol Infect Dis; 2009 Feb; 28(2):191-5. PubMed ID: 18758832
[TBL] [Abstract][Full Text] [Related]
24. Identification and management of unusual pathogens in cystic fibrosis.
Elborn JS
J R Soc Med; 2008 Jul; 101 Suppl 1(Suppl 1):S2-5. PubMed ID: 18607011
[No Abstract] [Full Text] [Related]
25. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.
Waters VJ; Gómez MI; Soong G; Amin S; Ernst RK; Prince A
Infect Immun; 2007 Apr; 75(4):1698-703. PubMed ID: 17220304
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.
Ritz N; Ammann RA; Casaulta Aebischer C; Schoeni-Affolter F; Schoeni MH
Eur J Pediatr; 2005 Sep; 164(9):577-82. PubMed ID: 15926067
[TBL] [Abstract][Full Text] [Related]
27. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.
Goss CH; Mayer-Hamblett N; Aitken ML; Rubenfeld GD; Ramsey BW
Thorax; 2004 Nov; 59(11):955-9. PubMed ID: 15516471
[TBL] [Abstract][Full Text] [Related]
28. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.
Miller MB; Gilligan PH
J Clin Microbiol; 2003 Sep; 41(9):4009-15. PubMed ID: 12958218
[No Abstract] [Full Text] [Related]
29. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2012 May; (5):CD009249. PubMed ID: 22592739
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.
Graff GR; Burns JL
Chest; 2002 Jun; 121(6):1754-60. PubMed ID: 12065335
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.
Talmaciu I; Varlotta L; Mortensen J; Schidlow DV
Pediatr Pulmonol; 2000 Jul; 30(1):10-5. PubMed ID: 10862157
[TBL] [Abstract][Full Text] [Related]
32. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients.
Marchac V; Equi A; Le Bihan-Benjamin C; Hodson M; Bush A
Eur Respir J; 2004 Jan; 23(1):98-102. PubMed ID: 14738239
[TBL] [Abstract][Full Text] [Related]
33. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Moss RB
Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
[TBL] [Abstract][Full Text] [Related]
34. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
Waters V; Atenafu EG; Salazar JG; Lu A; Yau Y; Matukas L; Tullis E; Ratjen F
J Cyst Fibros; 2012 Jan; 11(1):8-13. PubMed ID: 21849265
[TBL] [Abstract][Full Text] [Related]
35. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.
Amin R; Waters V
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD009249. PubMed ID: 27415821
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
